How does Senseonics aim to minimize the daily management burden for individuals living with type 1 and type 2 diabetes?
For two decades, Senseonics has focused on minimizing the time and effort involved with diabetes management, to enable a fuller life with fewer burdens for those with type 1 and type 2 diabetes. Our approach centers on simplifying diabetes management through technological advancements and innovation, to allow people with diabetes to focus more on living their lives than on managing their condition.
Senseonics works in collaboration with Ascensia Diabetes Care, leveraging a partnership that combines our innovation with their robust commercialization strategies. This synergy aims to deliver advancements to the market effectively and ensure that our contributions make a meaningful impact on the diabetes community.
What is Continuous Glucose Monitoring (CGM) and its significance?
CGM represents a leap forward in diabetes management, providing continuous glucose readings that offer a dynamic view of a person’s glucose levels in real time. This technology, which moves beyond traditional finger-stick tests, offers glucose data every five minutes, enabling better decision-making regarding diet, medication, and lifestyle adjustments. Particularly for people with diabetes on insulin therapy, CGM's real-time alerts and alarms offer a critical safety net, reducing the risks associated with nocturnal glucose fluctuations.
CGM technology has proven beneficial not only for individuals with type 1 diabetes but also for those with type 2 diabetes. The continuous insight into glucose levels facilitated by CGM devices has been instrumental in managing diabetes more effectively, showcasing significant clinical benefits and supporting the technology's adoption across both populations.
How is your Eversense CGM system different from other CGM systems in the market?
The Eversense E3 CGM system sets itself apart by being the only fully implantable sensor and the longest-lasting CGM system available. Unlike transcutaneous systems that require frequent replacements, Eversense provides a long-term solution with sensors that last for up to six months, thus reducing the burden of device management. This approach not only aligns with the goal of simplifying diabetes management but also highlights Senseonics' commitment to innovation in the field.
When it comes to the implantable nature of Eversense, the company emphasizes the extensive research and development undertaken to ensure the sensor's compatibility and longevity under the skin. Through advancements in this implantable technology, Senseonics has evolved its offerings from a sensor that lasts 90 days to one that lasts up to six months, with plans for a 365-day sensor. This evolution underscores our dedication to enhancing user experience and convenience.
How do regulatory approvals and market expansion plans shape the future of Senseonics and its CGM technology?
Senseonics navigates the complexities of regulatory approvals with a strategic focus on delivering our CGM solutions to a global audience. The company's history of innovation is marked by regulatory milestones, including the transition from a 90-day to a 180-day sensor, and plans for a 365-day product. Our proactive engagement with regulatory bodies like the FDA showcases a commitment to advancing diabetes care through technology.
The partnership between Senseonics and Ascensia Diabetes Care’s CGM team, under the leadership of Brian Hansen, is pivotal for leveraging global commercialization opportunities.
Ascensia's extensive experience in global diabetes care complements Senseonics' technological innovations, together aiming to broaden the availability of advanced CGM solutions. This collaboration underscores a shared vision for transforming diabetes management worldwide, focusing on scalability and patient-centric solutions.
What are the future developments in CGM technology at Senseonics?
Senseonics is at the forefront of pioneering longer-lasting and more flexible CGM solutions, with the Gemini and Freedom systems which are in development. These innovations will aim to further reduce the management burden on people with diabetes by eliminating external components and integrating directly with personal devices for seamless glucose monitoring. The focus on internal power sources and direct Bluetooth communication represents a significant leap towards making diabetes management as inconspicuous and convenient as possible.
These future technologies reflect Senseonics' ongoing commitment to pushing the boundaries of what's possible in diabetes care. By focusing on the needs and preferences of people with diabetes, Senseonics continues to lead in the development of solutions that will promise a more liberated and less cumbersome daily experience for users.
